MYCN and neoplasm: Aurora-A was shown to occupy the same binding region on MYCN as FBXW7, shielding MYCN from degradation [176], explaining why compounds that distort the Aurora-A kinase domain, untethering the Aurora-A/MYCN complex, also trigger MYCN destabilisation [176,193] and cause tumour regression in vivo in MYCN-driven neuroblastoma [194].